Hiscott John, Lacoste Judith, Lin Rongtuan
Lady Davis Institute for Medical Research-Jewish General Hospital, Department of Microbiology & Immunology, McGill University, Montreal, Canada H3T 1E2.
Biochem Pharmacol. 2006 Nov 30;72(11):1477-84. doi: 10.1016/j.bcp.2006.06.030. Epub 2006 Jul 31.
Recent advances in the understanding of the signaling pathways leading to the host antiviral response to hepatitis C virus (HCV), the mechanisms used by HCV to evade the immune response, and the development of small molecule inhibitors of HCV have generated optimism that novel therapeutic approaches to control HCV disease may soon be available. HCV infection is detected by the cytoplasmic, RNA helicase RIG-I that plays an essential role in signaling to the host antiviral response. Recently the adapter molecule that links RIG-I sensing of incoming viral RNA to downstream signaling and gene activation events was characterized by four different groups: MAVS/IPS-1-1/VISA/Cardif contains an amino-terminal CARD domain and carboxyl-terminal mitochondrial transmembrane sequence that localizes to the mitochondrial membrane. Furthermore, the hepatitis C virus NS3-4A protease complex specifically targets MAVS/IPS-1/VISA/Cardif for cleavage as part of its immune evasion strategy. Using a combination of biochemical analysis, subcellular fractionation and confocal microscopy, we demonstrate that: (1) NS3-4A cleavage of MAVS/IPS-1/VISA/Cardif causes relocation from the mitochondrial membrane to the cytosolic fraction, resulting in disruption of signaling to the antiviral immune response; (2) disruption requires a function NS3-4A protease; (3) a point mutant of MAVS/IPS-1/VISA/Cardif (Cys508Ala) is not cleaved from the mitochondria by active protease; and (4) the virus-induced IKK epsilon kinase, but not TBK1, co-localizes strongly with MAVS at the mitochondrial membrane and the localization of both molecules is disrupted by NS3-4A expression. These observations provide an outline of the mechanism by which HCV evades the IFN antiviral response.
在理解导致宿主对丙型肝炎病毒(HCV)产生抗病毒反应的信号通路、HCV用于逃避免疫反应的机制以及HCV小分子抑制剂的开发方面取得的最新进展,使人们乐观地认为,控制HCV疾病的新型治疗方法可能很快就会出现。HCV感染是由细胞质中的RNA解旋酶RIG-I检测到的,它在向宿主抗病毒反应发出信号中起重要作用。最近,连接RIG-I对进入病毒RNA的感知与下游信号传导和基因激活事件的衔接分子被四个不同的研究小组进行了表征:MAVS/IPS-1-1/VISA/Cardif包含一个氨基末端CARD结构域和一个羧基末端线粒体跨膜序列,定位于线粒体膜。此外,丙型肝炎病毒NS3-4A蛋白酶复合体作为其免疫逃避策略的一部分,特异性地靶向MAVS/IPS-1/VISA/Cardif进行切割。通过结合生化分析、亚细胞分级分离和共聚焦显微镜技术,我们证明:(1)MAVS/IPS-1/VISA/Cardif被NS3-4A切割后会从线粒体膜重新定位到细胞质部分,导致抗病毒免疫反应信号传导中断;(2)这种中断需要有功能的NS3-4A蛋白酶;(3)MAVS/IPS-1/VISA/Cardif的一个点突变体(Cys508Ala)不会被活性蛋白酶从线粒体上切割下来;(4)病毒诱导的IKKε激酶而非TBK1与MAVS在线粒体膜上强烈共定位,并且这两种分子的定位都会被NS3-4A的表达所破坏。这些观察结果概述了HCV逃避IFN抗病毒反应的机制。